Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Celdaz Dacarbazine Injection 500 mg
Celdaz contains 500 mg of dacarbazine, a potent alkylating agent used in oncology. It is employed in the management of various cancers, including malignant melanoma, Hodgkin's lymphoma, and sarcomas. Dacarbazine acts by disrupting DNA synthesis, thus inhibiting cancer cell proliferation.
Uses of Celdaz Dacarbazine Injection 500 mg
Treatment of Malignant Melanoma: Effective in treating malignant melanoma, particularly when other therapies have failed.
Management of Hodgkins Lymphoma: Used in combination with other drugs in the ABVD regimen for treating Hodgkin's lymphoma.
Treatment of Sarcomas: Applied in the treatment of soft tissue sarcomas and other solid tumors.
Adjuvant Therapy: Often used as part of a broader chemotherapy regimen to enhance treatment efficacy.
Benefits of Celdaz Dacarbazine Injection 500 mg
Effective Cancer Treatment: Provides a valuable option for managing specific cancers, particularly those resistant to other therapies.
Combination Therapy: Works effectively in combination with other chemotherapy agents, enhancing the overall treatment regimen.
Targeted Action: Disrupts DNA replication in cancer cells, thereby inhibiting tumor growth and spread.
Mechanism of Action of Celdaz Dacarbazine Injection 500 mg
Alkylating Agent: Dacarbazine is an alkylating agent that forms cross-links with DNA strands. This cross-linking inhibits DNA replication and transcription, leading to cell death.
DNA Disruption: The formation of these cross-links interferes with the cancer cells ability to divide and proliferate.
Selective Toxicity: Dacarbazine selectively targets rapidly dividing cancer cells, making it effective in treating various malignancies.